CHA Biotech
Financials
Valuation Metrics
CHA Biotech's Market Cap is ₩8832B. At end of 2025 it was ₩1.4T. Ranked #314 of 2,436 in KR market (top 13%), #84 of 1,649 on KOSDAQ (top 5%), #7 of 96 in Health Care Equipment & Services (top 7%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 883.24B KRW | KR#314/2,436 Sec#7/96 |
| Revenue | 1.29T KRW | KR#338/2,436 Sec#2/96 |
| Net Income | -122.35B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 2.79T KRW | KR#242/2,436 Sec#2/96 |
| Net Assets | 1.02T KRW | KR#282/2,436 Sec#2/96 |
| Employees | 334 | KR#716/2,436 Sec#19/96 |
| Value | ||
| P/B | 0.87x | KR#1,366/2,436 Sec#29/96 |
| P/S | 0.68x | KR#1,134/2,436 Sec#14/96 |
| FCF Yield | -24.85% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -12.03% | KR#1,939/2,436 Sec#64/96 |
| ROA | -4.39% | KR#1,860/2,436 Sec#59/96 |
| Op. Margin | -5.18% | KR#1,873/2,436 Sec#57/96 |
| Revenue Growth | 8.41% | KR#993/2,436 Sec#48/96 |
| Financial Health | ||
| Debt Ratio | 173.82% | KR#1,476/2,436 Sec#74/96 |
| Total Debt | 1.31T KRW | KR#164/2,436 Sec#1/96 |
| FCF | -219.51B KRW | KR#2,183/2,436 Sec#86/96 |
| Cash | 347.70B KRW | KR#181/2,436 Sec#1/96 |
| Current Ratio | 0.88x | KR#1,949/2,436 Sec#86/96 |
| Dividend | ||
| Div. Growth | -13.60% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | -12.28% | KR#1,035/2,436 Sec#29/96 |
| 1M Return | -9.18% | KR#1,709/2,436 Sec#68/96 |
| From 52W High | -60.33% | KR#1,724/2,436 Sec#60/96 |
| 1Y MDD | -66.33% | KR#1,761/2,436 Sec#60/96 |
| Trading | ||
| Volume | 390,403 shares | KR#333/2,436 Sec#11/96 |
| Foreign Own. | 8.53% | KR#535/2,436 Sec#15/96 |
| Per Share | ||
| EPS | -945 KRW | KR—/2,436 Sec—/96 |
| BPS | 5,534 KRW | KR#1,364/2,436 Sec#34/96 |
Company Info
CHA Biotech, established in 2002, engages in umbilical cord blood banking, stem cell research and cell therapy development, and anti-aging services. Through its major subsidiaries, the company operates pharmaceutical, global CDMO, and global medical network businesses, leveraging an ecosystem-based clinical and new drug development platform. Revenue generation is expected from advanced regenerative medicine treatment sales and global out-licensing. It is also strengthening its global network by establishing the world's largest Cell and Gene Therapy (CGT) manufacturing facility. CHA Biotech is headquartered in Gangnam-gu, Seoul.